Foventa Therapeutics CEO Olav Hellebø spoke to Business Weekly about the company’s refreshed identity and its ambitions as it prepares for a Series A raise. The story explores how the Cambridge biotech (formerly Exonate) has rebranded to reflect its evolution from a discovery‑stage organisation into a clinical‑stage company advancing FOV407, a first‑in‑class eye‑drop treatment for non‑proliferative diabetic retinopathy. With new leadership including Chief Medical Officer Dr Zaiba Malik and Chief Financial Officer Julia Jones, Foventa is positioning itself to scale its SRPK1 inhibitor platform and accelerate development of a therapy designed to intervene earlier in diabetic eye disease.

Hellebø outlines how FOV407 has progressed through Phase Ib/IIa studies and recently secured FDA Type C meeting validation for its Phase IIb design, marking a significant milestone as the company moves toward its next stage of growth. The rebrand signals a sharpened mission: to deliver a convenient, non‑invasive treatment option for millions of patients at risk of vision loss. Together, the leadership changes, clinical momentum and Series A ambitions illustrate a company entering a new chapter with a clear scientific rationale and a strong commercial trajectory.

Read the full story here.